For example, there is strong genetic evidence implicating both lipoprotein lipase (LPL) and angiopoietin-like protein 4 (ANGPTL4) as therapeutic targets for lipid-lowering and cardiovascular disease reduction [71]. Here, ANGPTL4 is linked to cardiovascular disorder.